Signature of a silent killer: expression profiling in epithelial ovarian cancer

With the sequencing of the human genome and the simultaneous development of high-throughput strategies, cancer biologists have entered an exciting new area for gene expression analysis, with the ability to glimpse higher order patterns of genetic and epigenetic alterations in complex diseases. Ovarian cancer biologists are rising to the challenge of applying these new technologies to this silent killer, with the eventual goal of improving the quality of life and long-term survival of patients. This review provides a summary of the disease, a description of available technologies and their application to the ovarian cancer problem, as well as a discussion on the challenges and opportunities related to DNA microarray expression profiling-based research, including downstream clinical applications.

[1]  William C Reinhold,et al.  Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling. , 2003, Cancer research.

[2]  R. Bast,et al.  Specific keynote: chemoprevention of ovarian cancer: the journey begins. , 2003, Gynecologic oncology.

[3]  B. Karlan,et al.  Surgical advances in the treatment of ovarian cancer. , 2003, Hematology/oncology clinics of North America.

[4]  Donald R Schwartz,et al.  Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. , 2003, Cancer cell.

[5]  Kathleen R. Cho,et al.  Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. , 2002, Cancer research.

[6]  Martin Fussenegger,et al.  Method for generation of homogeneous multicellular tumor spheroids applicable to a wide variety of cell types. , 2003, Biotechnology and bioengineering.

[7]  F. Ahmed.  MOLECULAR TECHNIQUES FOR STUDYING GENE EXPRESSION IN CARCINOGENESIS , 2002, Journal of environmental science and health. Part C, Environmental carcinogenesis & ecotoxicology reviews.

[8]  Michèl Schummer,et al.  The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. , 2003, Cancer research.

[9]  A. Jazaeri,et al.  Choice of normal ovarian control influences determination of differentially expressed genes in ovarian cancer expression profiling studies. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  David J. C. MacKay,et al.  A decomposition model to track gene expression signatures: preview on observer-independent classification of ovarian cancer , 2002, Bioinform..

[11]  Christos Sotiriou,et al.  Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. , 2002, Journal of the National Cancer Institute.

[12]  F. Marincola,et al.  High-fidelity mRNA amplification for gene profiling , 2000, Nature Biotechnology.

[13]  M. Crispens.  Borderline ovarian tumours: a review of the recent literature , 2003, Current opinion in obstetrics & gynecology.

[14]  T. Poggio,et al.  Multiclass cancer diagnosis using tumor gene expression signatures , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[15]  Gordon B Mills,et al.  Overexpression of kallikrein 10 in epithelial ovarian carcinomas. , 2003, Gynecologic oncology.

[16]  R. Berkowitz,et al.  Osteopontin as a potential diagnostic biomarker for ovarian cancer. , 2002, JAMA.

[17]  R. Scully.  Histological Typing of Ovarian Tumours , 1999, World Health Organization. International Histological Classification of Tumours.

[18]  M. Markman.  Optimizing primary chemotherapy in ovarian cancer. , 2003, Hematology/oncology clinics of North America.

[19]  D. Lockhart,et al.  Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[20]  T Tanaka,et al.  Identification by cDNA microarray of genes involved in ovarian carcinogenesis. , 2000, Cancer research.

[21]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[22]  M. White,et al.  Comparison of TP53 mutations identified by oligonucleotide microarray and conventional DNA sequence analysis. , 2000, Cancer research.

[23]  M. Heller.  DNA microarray technology: devices, systems, and applications. , 2002, Annual review of biomedical engineering.

[24]  C. Mathew,et al.  Disruption of the Fanconi anemia–BRCA pathway in cisplatin-sensitive ovarian tumors , 2003, Nature Medicine.

[25]  Tim Hui-Ming Huang,et al.  Triple analysis of the cancer epigenome: an integrated microarray system for assessing gene expression, DNA methylation, and histone acetylation. , 2003, Cancer research.

[26]  S. Mok,et al.  Identification of differentially expressed genes from ovarian cancer cells by MICROMAX cDNA microarray system. , 2001, BioTechniques.

[27]  D. Katsaros,et al.  Prognostic value of the human kallikrein gene 15 expression in ovarian cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Jeffrey R Marks,et al.  Gene Expression Patterns That Characterize Advanced Stage Serous Ovarian Cancers , 2004, The Journal of the Society for Gynecologic Investigation: JSGI.

[29]  T. Hudson,et al.  Patterns of expression of chromosome 17 genes in primary cultures of normal ovarian surface epithelia and epithelial ovarian cancer cell lines , 2003, Oncogene.

[30]  Monique Albert,et al.  Parallel analysis of sporadic primary ovarian carcinomas by spectral karyotyping, comparative genomic hybridization, and expression microarrays. , 2002, Cancer research.

[31]  R. L. Baldwin,et al.  Differential gene expression between normal and tumor-derived ovarian epithelial cells. , 2000, Cancer research.

[32]  J. Boyd.  Specific keynote: hereditary ovarian cancer: what we know. , 2003, Gynecologic oncology.

[33]  T. Okai,et al.  p53 mutations and overexpression affect prognosis of ovarian endometrioid cancer but not clear cell cancer. , 2003, Gynecologic oncology.

[34]  A. Aigner,et al.  Reversal of HER-2 over-expression renders human ovarian cancer cells highly resistant to taxol. , 2000, Toxicology.

[35]  G. Riggins,et al.  Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. , 2000, Cancer research.

[36]  J. Mesirov,et al.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.

[37]  R. Athwal,et al.  A gene on 6q 14-21 restores senescence to immortal ovarian tumor cells. , 1996, Oncogene.

[38]  L. Hood,et al.  Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray. , 1999, Gene.

[39]  R. Ozols.  Update on the management of ovarian cancer. , 2002, Cancer journal.

[40]  R. Berkowitz,et al.  Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. , 2001, Journal of the National Cancer Institute.

[41]  D. Katsaros,et al.  Higher human kallikrein gene 4 (KLK4) expression indicates poor prognosis of ovarian cancer patients. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[42]  S. Wadler,et al.  Phase I and pharmacologic study of i.p. 9-aminocamptothecin given as six fractions over 14 days , 2002, Anti-cancer drugs.

[43]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[44]  D. Slonim.  From patterns to pathways: gene expression data analysis comes of age , 2002, Nature Genetics.

[45]  F. Modugno.  Ovarian cancer and high-risk women-implications for prevention, screening, and early detection. , 2003, Gynecologic oncology.

[46]  D R Schwartz,et al.  Coordinately up-regulated genes in ovarian cancer. , 2001, Cancer research.

[47]  Christian A. Rees,et al.  Systematic variation in gene expression patterns in human cancer cell lines , 2000, Nature Genetics.

[48]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[49]  A. du Bois,et al.  State-of-the-Art First-Line Treatment of Ovarian Cancer , 2003, Oncology Research and Treatment.

[50]  T. Godfrey,et al.  Identification of genetic alterations related to chemoresistance in epithelial ovarian cancer. , 2003, Gynecologic oncology.

[51]  Trevor Hastie,et al.  Gene expression patterns in ovarian carcinomas. , 2003, Molecular biology of the cell.

[52]  Chris Cheadle,et al.  Development of a highly specialized cDNA array for the study and diagnosis of epithelial ovarian cancer. , 2002, Cancer research.

[53]  C. Morelli,et al.  Transfer of human chromosome 3 to an ovarian carcinoma cell line identifies three regions on 3p involved in ovarian cancer. , 1994, Oncogene.

[54]  C. Sotiriou,et al.  Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma , 2003, Molecular carcinogenesis.

[55]  A. Russell.  All, none, or some? , 2003, Gynecologic oncology.

[56]  L. Dubeau,et al.  Suppression of tumorigenicity in human ovarian cancer cell lines is controlled by a 2 cM fragment in chromosomal region 6q24-q25 , 1999, Oncogene.

[57]  Ann-Marie Martoglio,et al.  Changes in Tumorigenesis- and Angiogenesis-related Gene Transcript Abundance Profiles in Ovarian Cancer Detected by Tailored High Density cDNA Arrays , 2000, Molecular medicine.

[58]  Y Tenjin,et al.  Analysis of gene expression profiles associated with cisplatin resistance in human ovarian cancer cell lines and tissues using cDNA microarray. , 2001, Human cell.

[59]  Anne-Marie Mes-Masson,et al.  Microarray analysis of gene expression mirrors the biology of an ovarian cancer model , 2001, Oncogene.

[60]  R. L. Baldwin,et al.  Gene expression in epithelial ovarian carcinoma , 2002, Oncogene.

[61]  M. Ringnér,et al.  Molecular classification of familial non-BRCA1/BRCA2 breast cancer , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[62]  M. Markman.  Consolidation/maintenance chemotherapy for ovarian cancer , 2003, Current oncology reports.

[63]  I. Runnebaum,et al.  Epidemiological and molecular aspects of ovarian cancer risk , 2001, Journal of Cancer Research and Clinical Oncology.

[64]  D. Armstrong.  Relapsed ovarian cancer: challenges and management strategies for a chronic disease. , 2002, The oncologist.

[65]  T. Hudson,et al.  Expression profiles of 290 ESTs mapped to chromosome 3 in human epithelial ovarian cancer cell lines using DNA expression oligonucleotide microarrays. , 2002, Genome research.

[66]  Roger E Bumgarner,et al.  Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. , 1999, Gene.

[67]  Jason E. Stewart,et al.  Minimum information about a microarray experiment (MIAME)—toward standards for microarray data , 2001, Nature Genetics.

[68]  J. Kigawa,et al.  Multidrug resistance gene-1 is a useful predictor of Paclitaxel-based chemotherapy for patients with ovarian cancer. , 2002, Gynecologic oncology.

[69]  J. Berek,et al.  Ovarian cancer: epidemiology, biology, and prognostic factors. , 2000, Seminars in surgical oncology.

[70]  Wen Yang,et al.  Gene expression profile differences in high and low metastatic human ovarian cancer cell lines by gene chip. , 2002, Chinese medical journal.

[71]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[72]  K. Cole,et al.  Histopathology and molecular biology of ovarian epithelial tumors. , 1998, Annals of diagnostic pathology.

[73]  Soma Das,et al.  PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma , 2001, International journal of cancer.

[74]  Zhenfeng Duan,et al.  Molecular description of evolving paclitaxel resistance in the SKOV-3 human ovarian carcinoma cell line. , 2003, Cancer research.

[75]  E. Venkatraman,et al.  Identification of prognostic factors in advanced epithelial ovarian carcinoma. , 2001, Gynecologic oncology.